Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the possibility to repropose marketed drugs as antiviral
ones, based on their ability to reverse the transcriptomic signature of the infected cells.
This strategy has to be considered is the context of emerging viral diseases and of increase
of resistance to antivirals. Concerning infection by Influenza viruses, the main drugs were
identified and evaluated on in vitro and in vivo models: diltiazem. Therefore, it will be
assess the efficacy of these the drug, compared to placebo, to treat severe flu.